Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares MSCI Japan ETF (EWJ) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

EWJ, the iShares MSCI Japan ETF, trades at $94.55, up 1.1% today, with a bullish technical signal from moving averages. The fund tracks Japanese equities, facing currency headwinds as the yen weakens against the dollar. Recent news highlights potential FX intervention by Japanese authorities to support the yen, which could impact returns for USD-based investors. Technical indicators show support at $92 and resistance at $95, with neutral oscillators suggesting limited momentum.

The outlook for EWJ is mixed, with opportunities from Japan's domestic investment push and AI-driven stock gains, but risks include yen volatility and economic sensitivity. Investors should weigh currency-hedged options to mitigate FX drag, as structural reforms and pension fund shifts may offer long-term growth amid near-term uncertainty.